AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EyePoint Pharmaceuticals, Inc. Director's Dealing 2018

Jun 22, 2018

32254_dirs_2018-06-22_9722e8d2-f913-4b52-a74a-635b22f82023.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-06-14

Reporting Person: Ross Leonard S (See Remarks)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-14	Restricted Stock Units	$	A	24840	Acquired		Common Stock (24840)	Direct
2018-06-14	Stock Option (right to buy)	$2.04	A	99360	Acquired	2028-06-14	Common Stock (99360)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.

F2: The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.

F3: The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.